The groundbreaking rise of Viagra has long been a symbol of pharmaceutical success, but its future within the broader sector now triggers questions about future returns . Alternative versions are undercutting market share, prompting concerns that supporting companies heavily reliant to Viagra's former position could be a problematic strategy, espec